<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04340609</url>
  </required_header>
  <id_info>
    <org_study_id>CT/AMI/01/2019</org_study_id>
    <nct_id>NCT04340609</nct_id>
  </id_info>
  <brief_title>Stem Cell in Acute Myocardial Infarction</brief_title>
  <acronym>AMI</acronym>
  <official_title>Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT. Prodia Stem Cell Indonesia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT. Prodia Stem Cell Indonesia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will perform UC-MSCs transplantation in 2 groups and 1 control group with standard
      treatment. Each group consists of 5 subjects. In the first group UC-MSCs will be transplanted
      via intravenous (IV) route and the second group via intracoronary (IC) route. The IV group
      will receive 2 million cells/kg for each subject and the dosage of IC group is 50 million
      cells for each subject. All groups will be observed until 1 year.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2019</start_date>
  <completion_date type="Anticipated">March 11, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 11, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiac events (MACE) endpoints of mortality</measure>
    <time_frame>2 weeks after stem cell</time_frame>
    <description>To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major adverse cardiac events (MACE) endpoints of mortality</measure>
    <time_frame>3 months after stem cell</time_frame>
    <description>To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major adverse cardiac events (MACE) endpoints of mortality</measure>
    <time_frame>6 months after stem cell</time_frame>
    <description>To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major adverse cardiac events (MACE) endpoints of mortality</measure>
    <time_frame>12 months after stem cell</time_frame>
    <description>To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Re-infarction</measure>
    <time_frame>2 weeks after stem cell</time_frame>
    <description>To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Re-infarction</measure>
    <time_frame>3 months after stem cell</time_frame>
    <description>To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Re-infarction</measure>
    <time_frame>6 months after stem cell</time_frame>
    <description>To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Re-infarction</measure>
    <time_frame>12 months after stem cell</time_frame>
    <description>To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Target vessel revascularization (TVR)</measure>
    <time_frame>2 weeks after stem cell</time_frame>
    <description>To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Target vessel revascularization (TVR)</measure>
    <time_frame>3 months after stem cell</time_frame>
    <description>To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Target vessel revascularization (TVR)</measure>
    <time_frame>6 months after stem cell</time_frame>
    <description>To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Target vessel revascularization (TVR)</measure>
    <time_frame>12 months after stem cell</time_frame>
    <description>To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart failure hospitalization</measure>
    <time_frame>2 weeks after stem cell</time_frame>
    <description>To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart failure hospitalization</measure>
    <time_frame>3 months after stem cell</time_frame>
    <description>To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart failure hospitalization</measure>
    <time_frame>6 months after stem cell</time_frame>
    <description>To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart failure hospitalization</measure>
    <time_frame>12 months after stem cell</time_frame>
    <description>To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac MRI</measure>
    <time_frame>6 months after stem cell</time_frame>
    <description>a test to see improvement in LVEF(%), improvement in regional function, improvement in perfusion, reduction of infarct size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac MRI</measure>
    <time_frame>12 months after stem cell</time_frame>
    <description>a test to see improvement in LVEF (%), improvement in regional function, improvement in perfusion, reduction of infarct size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>6 months after stem cell</time_frame>
    <description>Left ventricular volumes will be determined at end-diastole and end-systole by quantitative biplane assessment. Endocardial borders will be manually traced from apical four-chamber and two-chamber views. Left ventricular volumes will be used to calculate ejection fraction using the biplane modified Simpson's summation-of-disks method recommended by the American Society of Echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>12 months after stem cell</time_frame>
    <description>Left ventricular volumes will be determined at end-diastole and end-systole by quantitative biplane assessment. Endocardial borders will be manually traced from apical four-chamber and two-chamber views. Left ventricular volumes will be used to calculate ejection fraction using the biplane modified Simpson's summation-of-disks method recommended by the American Society of Echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiography (ECG)</measure>
    <time_frame>3 months after stem cell</time_frame>
    <description>to detects cardiac (heart) abnormalities by measuring the electrical activity generated by the heart as it contracts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiography (ECG)</measure>
    <time_frame>6 months after stem cell</time_frame>
    <description>to detects cardiac (heart) abnormalities by measuring the electrical activity generated by the heart as it contracts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiography (ECG)</measure>
    <time_frame>12 months after stem cell</time_frame>
    <description>to detects cardiac (heart) abnormalities by measuring the electrical activity generated by the heart as it contracts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wellness Parameter</measure>
    <time_frame>6 months after stem cell</time_frame>
    <description>hs-CRP, antioxidant, IL-6, IL-10, PA1, Fibrinogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Assessment</measure>
    <time_frame>12 months after stem cell</time_frame>
    <description>Haematology, Serum Chemistry, Cardiac Biomarker</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Intravenous Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage of intravenous route is 2 million MSCs/kg for each subject.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intracoronary Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage of intracoronary route is ±50 million MSCs for each subject.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard treatment of acute myocardia infarction</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal Stem Cells</intervention_name>
    <description>The UC-MSCs from a donor will be cultured in a clinical grade laboratory with xeno-free medium. Maximum passage of expanded-UC MSCs was VI and doubling population is less than 30. To assure the quality of our expanded-UC MSCs at ProSTEM the following tests are done: cell adherence, cell surface marker, in vitro differentiation, cell viability, sterility, Mycoplasma, endotoxin, and karyotyping.</description>
    <arm_group_label>Intracoronary Group</arm_group_label>
    <arm_group_label>Intravenous Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  STEMI patients within 5 days after symptom onset of a first ST-segment elevation
             myocardial infarction

          -  Have undergone successful percutaneous coronary intervention (PCI) with drug eluting
             stent implantation of the infarct-related artery and demonstrated hypokinesia or
             akinesia that involved more than two thirds of the LV anteroseptal, lateral, or
             inferior wall with LV ejection fraction of &lt; 45% by echocardiography.

          -  Ability to understand and provide signed informed consent, or have a designated legal
             guardian or spouse legally able and willing to make such decisions on the subject's
             behalf,

          -  Willingness to attend all scheduled safety follow-up visits

          -  Subjects need to have a specific criteria of having a single vessel disease (ostial or
             proximal LAD vessels) that caused extensive anterior infarction (EF &lt;45).

        Exclusion Criteria:

          -  Hemodynamic instability as demonstrated by any of the following,

          -  Requirement of intra-aortic balloon pump of left ventricular assist device,

          -  Need for inotropic support (e.g. dopamine and/or dobutamine) for more than 36 hours
             for the maintenance of mean arterial blood pressure ≥ 60 mmHg,

          -  Previous or current concomitant serious illnesses, such as cancer, hematological
             disorders (Hb &lt; 10 g/dL, WBC &lt; 4 or &gt; 11x109/L, or platelets &lt; 100x109/L), kidney
             failure (creatinine level &gt; 2.5 mg/dL, or creatinine clearance &lt; 30 cc/min), serious
             infection or any other co-morbidities that could impact patient's short-term survival,
             psychiatric illness, history of drug of alcohol abuse,

          -  Prosthetic valves,

          -  Hypertrophic or restrictive cardiomyopathy,

          -  Women of child-bearing potential,

          -  Inability to comply with the protocol,

          -  Currently using implantable electronic defibrillator or pacemaker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Teguh Santoso, Professor</last_name>
    <phone>088293176579</phone>
    <email>profteguhsantosos@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cynthia Retna Sartika, Dr</last_name>
    <email>c.sartika@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>PT Prodia StemCell Indonesia</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 8, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2020</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allogeneic Mesenchymal Stem Cells</keyword>
  <keyword>Umbilical Cord Mesenchymal Stem Cells</keyword>
  <keyword>Intravenous Mesenchymal Stem Cells</keyword>
  <keyword>Intracoronary Mesenechymal Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

